Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions.
JournalItem (Reviews, Editorials, Rezensionen, Urteilsanmerkungen etc. in einer wissenschaftlichen Zeitschrift)
 
ID 4627072
Author(s) Jeiziner, Chiara; Stäuble, Céline K; Lampert, Markus L; Hersberger, Kurt E; Meyer Zu Schwabedissen, Henriette E
Author(s) at UniBasel Meyer zu Schwabedissen, Henriette
Jeiziner, Chiara
Hersberger, Kurt
Stäuble, Céline
Lampert, Markus Leopold
Year 2021
Title Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions.
Journal Pharmacogenomics and personalized medicine
Volume 14
Pages 279-286
Keywords CYP2C19; CYP2C9; CYP2D6; PGx; medication review; pharmacogenetics; tamoxifen
Abstract

Pharmacogenotyping is applied to determine the hereditable component of a patient's susceptibility to experience therapy failure and/or adverse drug reactions (ADRs). We present the case of a female patient diagnosed with breast cancer and treated with tamoxifen as recurrence therapy who experienced various ADRs. Pharmacogenotyping revealed variants in the cytochrome P450 (CYP) enzymes CYP2D6, CYP2C9, and CYP2C19. The observed genotype was associated with a risk for lower tamoxifen efficacy. Aside from the tamoxifen therapy, the comedication was reviewed for the influence of the patient's pharmacogenetic profile. As a result of this pharmacist-led medication review with pharmacogenetic analyses, concrete genotype-driven recommendations for the treating gynecologist were compiled. This case revealed the added value of a large pharmacogenetic panel and the complexity of integrating a pharmacogenetic profile into a recommendation.

ISSN/ISBN 1178-7066
Full Text on edoc
Digital Object Identifier DOI 10.2147/PGPM.S285807
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/33642872
   

MCSS v5.8 PRO. 0.452 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
04/12/2022